Speaker
Description
Ionetix Corporation has been conducting research and development on compact superconducting cyclotrons for medical isotope production, with multiple Ion-12SC units installed and operated at customer sites in USA. Since 2021, we have also focused on the production of alpha-emitting medical isotopes for cancer therapy, specifically At-211 and Ac-225. As a first step, Ionetix acquired an existing, partial CS-30 Cyclotron system decommissioned and stored in a warehouse. We refurbished and upgraded the CS-30 cyclotron, replacing components as needed. The installation of the CS-30 was completed in 2022, and it has been operational, accelerating alpha and proton beams since 2023. The refurbished cyclotron features new main and trim coils, a new internal bismuth target and drive, and a new central region to enhance the beam-on-target performance. All power supplies, controls, and instrumentation were replaced with commercially available components. The first production of At-211 at Ionetix was achieved in April 2023, followed by the first production of Ac-225 in June 2024. This paper analyzes and describes the CS-30 cyclotron, and the upgrades and enhancements developed at Ionetix.
| Region represented | America |
|---|---|
| Paper preparation format | Word |
